SIGY (Sigyn Therapeutics) Cyclically Adjusted PB Ratio: (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Sigyn Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sigyn Therapeutics  (OTCPK:SIGY) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Sigyn Therapeutics Cyclically Adjusted PB Ratio Related Terms


Sigyn Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Sigyn Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sigyn Therapeutics Cyclically Adjusted PB Ratio Chart

Sigyn Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Sigyn Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SIGY vs CNBX, LIPO, CARM: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Sigyn Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sigyn Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sigyn Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Sigyn Therapeutics's Cyclically Adjusted PB Ratio falls into.



Sigyn Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Sigyn Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2025 is calculated as:

For example, Sigyn Therapeutics's adjusted Book Value per Share data for the three months ended in Sep. 2025 was:

Adj_Book=Book Value per Share/CPI of Sep. 2025 (Change)*Current CPI (Sep. 2025)
=-3.687/324.8000*324.8000
=-3.687

Current CPI (Sep. 2025) = 324.8000.

Sigyn Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201512 -196.833 236.525 -270.294
201603 -69.167 238.132 -94.340
201606 -162.500 241.018 -218.988
201609 -207.000 241.428 -278.483
201612 -98.857 241.432 -132.993
201703 -174.286 243.801 -232.190
201706 -213.875 244.955 -283.589
201709 -373.500 246.819 -491.505
201712 -232.667 246.524 -306.543
201803 -240.100 249.554 -312.495
201806 -246.400 251.989 -317.596
201809 -223.500 252.439 -287.566
201812 -265.357 251.233 -343.060
201903 -261.500 254.202 -334.125
201906 -269.857 256.143 -342.190
201909 -279.786 256.759 -353.929
201912 -175.786 256.974 -222.183
202003 -171.267 258.115 -215.514
202006 -166.813 257.797 -210.169
202009 -176.188 260.280 -219.863
202012 0.113 260.474 0.141
202103 -0.091 264.877 -0.112
202106 1.067 271.696 1.276
202109 0.390 274.310 0.462
202112 -0.284 278.802 -0.331
202203 -0.785 287.504 -0.887
202206 -1.269 296.311 -1.391
202209 -1.869 296.808 -2.045
202212 -1.989 296.797 -2.177
202303 -2.197 301.836 -2.364
202306 -2.750 305.109 -2.927
202309 -3.233 307.789 -3.412
202312 -2.650 306.746 -2.806
202403 -3.282 312.332 -3.413
202406 -2.905 314.175 -3.003
202409 -2.761 315.301 -2.844
202412 -2.778 315.605 -2.859
202503 -3.081 319.799 -3.129
202506 -3.388 322.561 -3.412
202509 -3.687 324.800 -3.687

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sigyn Therapeutics Business Description

Address 2468 Historic Decatur Road, Suite 140, San Diego, CA, USA, 92106
Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths world-wide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the world-wide infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.